Myths in migraine research: 1. Migraine and cluster headache patients are characterized by significant alterations in platelet monoamine oxidase activity

Headache Quarterly

Volumn 7, Issue 3, 1996, Pages 225-234

  Mosnaim, Aron D ^a   Wolf, Marion E ^c,d   Curr, Maureen ^b   Mosnaim, Janet N ^e   Freitag, Frederick G ^f,g   Diamond, Seymour ^b,h  

^a Dept of Pharmacol and Molec Biol ^*  (United States)

^b ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e BRANDEIS UNIVERSITY   (United States)

^f DIAMOND HEADACHE CLINIC   (United States)

^g MIDWESTERN UNIVERSITY   (United States)

^h Diamond Inpatient Headache Unit   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); BIOLOGICAL MARKER; CANNABIS; PSYCHOTROPIC AGENT;

CANNABIS ADDICTION; CLUSTER HEADACHE; ENZYME ACTIVITY; HUMAN; MIGRAINE; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; REVIEW; SMOKING; THROMBOCYTE; TOBACCO;

EID: 0029739015     PISSN: 10597565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. Adolfsson R, Gottfries CG, Oreland L, Wiberg A, Winbland B. Increased activity of brain and platelet monoamine oxidase activity in dementia of Alzheimer type. Life Sci. 27:1029-1034.
2. Aldinio C, Cerletti C, Manara L, Recchia M. Human platelet monoamine oxidase in glaucoma. Investigat Ophthalmol Visual Sci. 1979; 18:320-324.
3. Anselmi B, Buffoni E, Curradi C, Del Bianco PL, Sicuteri F. Monoamine oxidase defect in essential arterial hypertension. A single dose pargyline test. Monographs Neural Sci. 1976; 3:115-123.
4. Baldessarini RJ. Drugs and the treatment of psychiatric disorders. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edition (Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman LE, eds). New York: McGraw-Hill; 1996; 383-435.
5. Ballenger JC, Post RM, Jimerson DC, Lake CR, Murphy D, Zuckerman M, et al. Biochemical correlates of personality traits in normals: An exploratory study. Personality Individ Differ. 1983; 4:615.
6. Balon R, Rainey JM, Pohl R, Yeragni VK, Oxenkrug GF, McCauley RB. Platelet monoamine oxidase activity in panic disorder. Psychiat Res. 1987; 22:37-41.
7. Belendiuk K, Belendiuk GW, Freedman DX. Blood monoamine metabolism in Huntington's disease. Arch Gen Psychiat. 1980; 37:325-332.
8. Belmaker RH, Murphy DL, Wyatt RJ, Loriaux L. Human platelet monoamine oxidase changes during the menstrual cycle. Arch Gen Psychiat. 1974; 31:553-559.
9. Benson PF, Southgate J. Diminished activity of monoamine oxidase in Down's syndrome. Am J Hum Gen. 1971; 23:211-214.
10. Bieck PR, Muehlbauer B, Antonin KH. Differential effects of brofaromine and moclobemide on melatonin secretion. In: Psychiatry Today. 7th World Congress of Psychiatry, Athens. (Stefanis CN, Soldatos CR, Rabavilas C, eds). Amsterdam: Excerpta Media; 1989.
11. Bockar F, Roth R, Heninger G. Increased platelet monoamine oxidase activity during lithium carbonate therapy. Life Sci. 1974; 15:2109-2118.
12. Brown JB. Platelet MAO and alcoholism. Am J Psychiat. 1977; 134:206-207.
13. Buchsbaum MS, Coursey RD, Murphy DL. The biochemical high-risk paradigm: Behavioural and familial correlates of low platelet monoamine oxidase activity. Science (NY). 1976; 194:339-341.
14. Bussone G, Giovanini P, Boiardi A, Boeri R. A study of the activity of platelet monoamine oxidase in patient with migraine headaches or with "cluster headaches." Eur Neurol. 1977; 15:157-162.
15. _ Boiardi A, Cerrati A, Girotti F, Merati B, Rivolta G. Monoamine oxidase activities in patients with migraine or with cluster headaches during the acute phase and after treatment with L-hydroxytryptophan. Riv Pat Nerv Ment. 1979; 100:269-274.
16. Caramona MM, Cotrim MD, Fontes Ribeiro C, Macedo T. Monoamine oxidase activity in blood platelets of migraine patients. J Neural Transm. 1990; 32:161-164.
17. Cesura AM, Richards JG, Picotti GB, Kettler R, Imhof R, Da Prada M. Reversible monoamine oxidase inhibitors: From laboratory to clinic. In: Monoamine Oxidase: Basic and Clinical Aspects (Yasuhar H, Pavez SH, Oguchi K, Sandler N, Nagatsu T, eds). Utrecht: VSP 1993; 159-176.
18. Corash L, Costa JL, Shafer B, Danlon JA, Murphy D. Heterogeneity of human blood platelet subpopulations. III. Density-dependent differences in subcellular constituents. Blood. 1984; 64:185-193.
19. Costa E, Sandler M (eds). Monoamine Oxidase-New Vistas. Advances in Biochemical Psychopharmacology. Vol 5. New York: Raven Press, 1972.
20. Dalessio DJ, Silberstein SD (eds). Wolff's Headache and Other Head Pain. 6th edition. New York: Oxford University Press; 1993.
21. Danielczyk W, Streifler M, Konradi C, Riederer P, Moll G. Platelet MAO-B activity and the psychopathology of Parkinson's disease, senile dementialand multi-infarct dementia. Acta Psychiatr Scand. 1988; 78:730-736.
22. Da Prada M, Kettler R, Keller HH, Cesura AM, Richards JG, Saura Marti J, et al. From moclobemide to Ro 19-6327 and to Ro 41-1049: The development of a new class of reversible, selective MAO-A and MAO-B inhibitors. J Neural Transm. 1990; 29:279-292.
23. Davidson J, Lipper S, Kilts CD, Mahorney S, Hammett E. Platelet MAO in post-traümatic stress disorder. Am J Psychiat. 1985; 142:1341-1343.
24. Davis BA, Dawson B, Boulton AA, Yu PH, Durden DA. Investigation of some biological trait markers in migraine: Deuterated tyramine challenge test, monoamine oxidase, phenolsulfotransferase and plasma and urinary biogenic amine and acid metabolite levels. Headache. 1987; 27:384-389.
25. Diamond S, and Dalessio DJ. (eds). The Practicing Physician's Approach to Headache, 5th edition. Baltimore: Williams & Wilkins; 1992.
26. Ferrari MD, Odink J, Tapparelli C, Van Kempen GM, Pennings EJ, Bruyn GW. Serotonin metabolism in migraine. Neurology. 1989; 39:1239-1242.
27. Fieve RR, Kumbarachi T, Kassir S, Dunner DL, Cote L. Platelet monoamine oxidase activity in affective disorder. Biol Psychiat. 1980; 15:473-478.
28. 12 in dementia. Biol Psychiat. 1994; 35:772-774.
29. Fiaskos J, George AJ, Theophilopoulos N. Symptoms of agoraphobia in relation to monoamine oxidase activity. Clin Neuropharmacol. 1984; 7:180-181.
30. Fleissner A, Seifert R, Schnieder K, Eckert W, Fuisting B. Platelet monoamine oxidase activity and schizophrenia - A myth that refuses to die. Eur Arch Psychiat Neurol Sci. 1987; 237:8-15.
31. Fowler CJ, Ekstedt B, Eggshira T, Kinemichi H, Oreland L The interaction between human platelet monoamine oxidase its monoamine substrates and oxygen. Biochem Pharmacol. 1979; 28:3063-3068.
32. _ Tipton KF, Mackay AVP, Youdim MBH. Human platelet monoamine oxidase, a useful enzyme in the study of psychiatric disorders? Neuroscience. 1982; 7:1577-1594.
33. Friedhoff AJ, Miller JC, Karpatkin S. Heterogeneity of human platelets. VII. Platelet monoamine oxidase in normals and patients with autoimmune thrombocytopenic purpura and reactive thrombocytosis: Its relationship to platelet protein density. Blood. 1978; 51:317-323.
34. Gattaz WF, Beckman H. Platelet MAO activity and personality characteristics: A study in schizophrenic patients and normal individuals. Acta Psychiatr Scand. 1981; 63:479-485.
35. Gershon ES, Lynn RG, Lake CR, Murphy DL, Guroff JJ. Genetics of plasma dopamine-beta-hydroxylase (DBH) erythrocyte catechol-o-methyltransferase (COMT), and platelet monoamine oxidase (MAO) in pedigrees of patients with affective disorders. In: Enzymes and Neurotransmitters in Mental Disease. (Usdin E, Sourkes TL, Yodim MBH, eds). Chichester, England: John Wiley and Sons. 1980; 281-299.
36. Glover V, Sandier M, Grant E, Rose F, Orton D, Wilkinson M, et al. Transitory decrease in platelet monoamine oxidase activity during migraine attacks. Lancet. 1977; i:391-393.
37. _ Hughes A, Hoffbrand AV. Platelet monoamine oxidase activity in megaloblastic anaemia. J Clin Pathol. 1980; 33:963-965.
38. _ Peatfield R, Zammit-Pace R, Littlewood J, Gawel M, Rose FC, et al. Platelet monoamine oxidase activity and headache. J Neurol Neurosurg Psychiat. 1981; 44:786-790.
39. Gorman J, Liebowitz MR, Fyer AJ, Levitt M. Platelet monoamine oxidase activity in patients with panic disorder. Biol Psychiat. 1985; 29:852-857.
40. Grant ECG. Monoamine oxidase activity in migraine. Lancet. 1978; ii:679. (Letter)
41. _ Carroll JD, Pryse-Davies J. Monoamine oxidase and migraine. Lancet. 1974; ii:1449. (Letter)
42. Guicheney P, Soliman H, Launay GM, Dreux C, Meyer P. Circulating monoamine oxidase B and phenolsulfotransferase activities in essential hypertensive patients. Clin Exper Hyperten. 1988; 10:533-544.
43. Hallman J, Oreland L, Edman G, Schalling D. Thrombocytce monoamine oxidase activity and personality traits in women with severe premenstrual syndrome. Acta Psychiatr Scand. 1987; 76:225-234.
44. Hanington E. Monoamine oxidase and migraine. Lancet. 1974; ii:1148-1150.
45. Hanington H, Jones RJ, Ames JAL. Migraine, a platelet disorder. Lancet 1981; ii:720-723.
46. Hardman JB, Limbird LE, Molinoff PB, Ruddon RW, Golman AG, (eds). In: Goodman and Gilman's. The Pharmacological Basis of Therapeutics, 9th edition. New York: Pergamon Press; 1996.
47. Jeste DV, Neckers LM, Wagner RL, Wise CD. Lymphocyte monoamine oxidase and plasma prolactin and growth hormone in tardive dyskinesia. J Clin Psychiat. 1981; 42:75-77.
48. Johnstone JP. Some observations upon a new inhibitor of monoamine oxidase in human brain. Biochem Pharmacol. 1968; 17:1285-1297.
49. Knoll J, Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol. 1972; 5:393-408.
50. Kovacs K, Tothfalusi L, Herman F, Magyar K. MAO activity, serotonin metabolism and aggregation of platelets from migraine patients. A preliminary study. Pol J Pharmacol Pharm. 1988, 40:461-465.
51. _ Jelencsik K. Csanda E, Magyar K. Changes in monoamine oxidase (MAO) activity in migraine. Acta Physiol Hunger. 1990; 75:181-182.
52. Krajl M. Arapid microfluorometric determination of MAO. Biochem Pharmacol. 1965; 684-686.
53. Lance JW. The pathophysiology of migraine. In: Wolff's Headache and Other Head Pain, 6th edition (Dalessio DJ, Silberstein SD, eds). New York: Oxford University Press; 1993; 59-65.
54. Littlewood J, Glover V, Sandler M, Peatfield R, Petty R, Rose FC. Low platelet monoamine oxidase activity in headache: No correlation with phenolsulphotransferase, succinate dehydrogenase, platelet preparation method or smoking. J Neurol Neurosurg Psychiat. 1984; 47:338-343.
55. Mann JJ, Chiu E. Platelet monoamine oxidase activity in Huntington's chorea. J Neurol Neurosurg Psychiat. 1978; 41:809-812.
56. Marcolin MA, Davis JM. Platelet monoamine oxidase in schizophrenia: A meta analysis. Schizophrenia Res. 1992; 7:249-267.
57. Mathew NT (ed). Cluster Headache. New York: Spectrum Publications, 1984.
58. McCaman RE, McCaman MW, Hunt JM. Microdetermination of monoamine oxidase and 5-hydroxytryptophan decarboxylase activities in nervous tissues. J Neurochem. 1965; 12:15-23.
59. Meltzer HY, Arora RC. Platelet markers of suicidality. Ann NY Sci. 1986; 487:271-280.
60. Morgenstern H, Hafez HM, Glazer WH, Giller E Jr, Zahner G. Platelet monoamine oxidase activity and tardive dyskinesia. Psychiat Res. 1988; 25:163-171.
61. Mosnaim AD, Wolf ME (eds). Noncatecholic Phenylethylamines. Part 1. Phenylethylamine: Biological Mechanisms and Clinical Aspects. New York: Marcel Dekker; 1978.
62. _ Huprikar S, Singh SP, Zeller EA. Reduced monoamine oxidase activity in blood platelets form insulin-dependent diabetic subjects. Diabetes. 1979; 28:455-456.
63. _ eds. Noncatecholic Phenylethylamines, Part 2. Phenylethanolamine, Tyramines and Octopamine. New York: Marcel Dekker; 1980.
64. _ Wine R, Karoum F, Diamond S, Wolf, M.E. Methionineenkephalin, phenylethylamine, phenylacetic acid, monoamine oxidase activity and prolactin in plasma of migraine patients. Clin Pharmacol Ther. 1982; 31:251-252.
65. _ Karoum F, Zeller, EA, Callaghan OH, Singh Z, Wolf ME. Platelet monoamine oxidase activity and plasma levels of non-catecholic phenylethylamines in insulin-dependent diabetic subjects. Clin Chim Acta 1982b; 126:237-242.
66. _ Huprikar S, Wolf ME, Diamond S. Platelet monoamine oxidase in female migraine patients. Headache. 1990; 30:448-490.
67. _ Freitag FG, Diamond S. Studies of platelet MAO activity in female migraineurs. An old story revisited. In: New Advances in Headache Research: 2 (Rose FC, ed). London:Smith-Gordon, 1991; 135-139.
68. _ Callaghan OH, Freitag F, Diamond S. Platelet monoamine oxidase activity in cluster headache patients. Headache. 1992; 3:172-176.
69. _ Wolf ME, Maturana P, Puente J, Freitag FG, Diamond S. In vitro studies of natural killer cell activity in migraineurs. Changes in response to a B-endorphin challenge during an acute migraine episode. Headache Quart. 1994; 5:142-149.
70. Murphy D, Weiss R. Reduced monoamine oxidase activity in blood platelets from bipolar depressed patients. Am J Psychiat. 1972; 128:1351-1357.
71. _ Donnelly CH, Miller L, Wyatt RJ. Platelet monoamine oxidase in schizophrenia. Schizophrenia Bull. 1976; 2:77-89.
72. Nilsson SE, Tryding N, Tufvesson G. Serum monoamine oxidase (MAO) in diabetes mellitus and some other internal diseases. Acta Med Scand. 1968; 184:105-108.
73. Norman TR, Chamberlain KG, French MA, Burrows GD., Platelet monoamine oxidase activity and cigarette smoking. J Affective Disord. 1982; 4:73-77.
74. _ Acevedo A, Mclntyre IM, Judd FK, Burrows GD. A kinetic analysis of platelet monoamine oxidase activity in patients with panic attacks. J Affective Disord. 1988; 15:127-130.
75. Oreland L, Wiberg A, Asberg M, Traskman L, Sjostrand L, Thoren P, et al. Platelet MAO activity and monoamine metabolites in cerebrospinal fluid in depressed and suicidal patients and in healthy controls. Psychiat Res. 1981; 4:21-29.
76. _ Fowler CJ. Brain and platelet monoamine oxidase activities in relation to central monoaminergic activity in mice and man. In: Monoamine Oxidase: Basic and Clinical Frontiers (Kamijo K, Usdin E, Nagatsu T, eds). Amsterdam: Excerpta Medica; 1982; 312-320.
77. _ von Knorring L, von Knorring AL, Bohman M. Studies on the connection between alcoholism and low platelet monoamine oxidase activity. In: Alcohol Nutrition and the Nervous System (Parvez S, Burns E. Burrov Y, Parvez H, eds). Utrecht: VNU Science Press; 1985; 83-117.
78. Peatfield R. Headache. Berlin: Springer-Verlag; 1986.
79. Perris C, Eisemann M, von Knorring L, Oreland L, Perris H. Personality traits and MAO activity in platelets in depressed patients. Neuropsychobiology. 1984; 12:201-205.
80. 12 levels are related to high activity of platelet MAO in patients with dementia disorders. Acta Psychiatr Scand. 1988; 78-451-457.
81. Robinson DS, Lovenberg W, Kaiser H, Sjoerdsma A. Effect of drugs on human blood platelet and plasma monoamine oxidase activity in vitro and in vivo. Biochem Pharmacol. 1968; 17:109-119.
82. Samson JA, Gudeman JE, Schatzberg AF, Kizuka PP, Orsulak PJ, Cole JO, et al. Toward a biochemical classification of depressive disorders. VIII. Platelet monoamine oxidase activity in subtypes of depression. J Psychiatr Res. 1985; 19:547-555.
83. Sandler M, Youdim MBH, Hanington E. A phenylethylamine oxidizing defect in migraine. Nature. 1974; 250:335-337.
84. _ Reveley MA, Glover V. Human platelet monoamine oxidase activity in health and disease: A review. J Clin Pathol. 1981; 334:292-302.
85. Schalling D, Asberg M, Oreland L, Edman G. Markers for vulnerability to psychopathology. Temperament traits associated with platelet MAO activity. Acta Psychiatr Scand. 1987; 76:172-182.
86. Sicuteri F, Buffoni F, Anselmi B, del Bianco PL. An enzyme (MAO) defect on the platelets in migraine. Res Clin Stud Headache. 1972; 3:245-251.
87. Singer TP, Ramsay RR. New aspects of the substrate specificities, kinetic mechanisms and inhibition of monoamine oxidase. In: Monoamine Oxidase: Basic and Clinical Aspects (Yasuhara H, Parvez SH, Oguchi K, Sandier M, Nagatsu T, eds). Utrecht: VPS; 1993; 23-43.
88. Shih JC. cDNA cloning of human liver MAO-A and MAO-B. In: Monoamine Oxidase: Basic and Clinical Aspects (Yasuhara H, Parvez SH, Oguchi K, Sandier M, Nagutsu T, eds). Utrecht: VPS; 1993; 15-21.
89. Stillman RC, Wyatt RJ, Murphy DL, Rauscher FP. Low platelet monoamine oxidase activity and chronic marijuana use. Life Sci. 1978; 23:1577-1582.
90. Summers KM, Brawn GK, Craig IW, Uttlewood J, Peatfield R, Glover V, et al. Platelet monoamine oxidase: Specific activity and turnover number in headache. Clin Chim Acta. 1982; 121:139-146.
91. Tabakoff B, Hoffman PL, Lee JM, SaitoT, Willard B, De Leon-Jones F. Differences in platelet enzyme activity between alcoholics and non-alcoholics. N Engl J Med. 1988; 318:134-139.
92. Thomas DV. Platelet monoamine oxidase in migraine. In: Advances in Neurology, Volume 33 (Critchley M, Gorini S, Friedman A, Sicuteri F, eds). New York: Raven Press; 1982; 279-281.
93. Tipton KF, Youdim MB. Beef adrenal medulla monoamine oxidase. Biochem Pharmacol. 1968; 17:109-119.
94. Van Kampen EJ, Zijlstra WG. Determination of hemoglobin and its derivatives. Adv Clin Chem. 1965; 8:141-187.
95. Van Kampen GM, Van Brussel JL, Penning EJ. Assay of platelet monoamine oxidase in whole blood. Clin Chim Acta. 1982; 121:139-146.
96. Waldenlind E, Saaf J, Ekbom K, Svante R, Wahlund LO, Wetterberg L. Kinetics and thermolability of platelet monoamine oxidase in cluster headache and migraine. Cephalalgia. 1984; 4:125-134.
97. Wiberg A, Gottfries CG, Oreland L. Low platelet monoamine oxidase activity in human alcoholics. Med Biol. 1977; 55:181-186.
98. Wurtman RJ, Axelrod J. A sensitive and specific assay for the estimation of monomaine oxidase. Biochem Pharmacol. 1963; 12:1439-1441.
99. Wyatt RJ, Murphy DL, Belmaker R, Cohen S, Donnelly CH, Pollin W. Reduced monoamine oxidase activity in platelets: A possible genetic marker for vulnerability to schizophrenia. Science. 1973; 179:916-918.
100. _ Potkin SG, Murphy DL. Platelet monoamine oxidase activity in schizophrenia; A review of the data. Amer J Psychiat. 1979; 136:377-385.
101. Yang H-YT, Neff NH. B-Phenylethylamine: A specific substrate for type B monoamine oxidase. J Pharmacol Exp Ther. 1973; 187:365-371.
102. Yasuhara H, Parvez SH, Oguchi K, Sandller M, Nagatsu T. (eds). Monoamine Oxidase: Basic and Clinical Aspects. Utrecht: VSP; 1993.
103. Youdim MB, Grahame-Smith DG, Woods HF. Some properties of human platelet monoamine oxidase in iron-deficiency anemia. Clin Sci Mol Med. 1976; 50:479-485.
104. Yu PH, Bowen R, Carlson K, O'Sullivan K, Bolton AA. Comparison of biochemical properties of platelet monoamine oxidase in mentally disordered and healthy individuals. Psychiatr Res. 1982; 6:107-121.
105. _ Davis BA, Bowen RC, Wormith S, Addington D, Boulton AA. Platelet monoamine oxidase activity and plasma trace acid levels in agoraphobic patients and violent offenders. In: Monoamine Oxidase and Disease (Tipton KF, Dostert, P, Strolin-Benedetti M, eds). London: Academic Press; 1984; 643-644.
106. Zeller EA, Barsky B: In vivo inhibition of liver and brain monoamine oxidase by I-isonicotinyl hydrazine. Proc Soc Exp Biol Med. 1952; 81:459-461.
107. _ Huprikar S, Gibbons RD, Millar A. Influence of age, sex, and osteogenesis imperfecta on count, protein content, and monoamine oxidase activity of human thrombocytes. Clin Chim Acta. 1984; 137:1231-1239.